RT Journal Article
SR Electronic
T1 Estimating Indirect Costs in Primary Sjögren’s Syndrome
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 1010
OP 1015
DO 10.3899/jrheum.090734
VO 37
IS 5
A1 SIMON J. BOWMAN
A1 YVAN ST. PIERRE
A1 NURHAN SUTCLIFFE
A1 DAVID A. ISENBERG
A1 FIONA GOLDBLATT
A1 ELIZABETH PRICE
A1 JOHN HAMBURGER
A1 ANDREA RICHARDS
A1 SAAEHA RAUZ
A1 MARIAN REGAN
A1 SHIRLEY RIGBY
A1 ADRIAN JONES
A1 DIARMUID MULHERIN
A1 ANN E. CLARKE
YR 2010
UL http://www.jrheum.org/content/37/5/1010.abstract
AB Objective. To estimate the indirect costs associated with primary Sjögren’s syndrome (pSS) compared with rheumatoid arthritis (RA) and community controls. Methods. Data were obtained from 84 women patients with pSS as part of a study to develop a systemic activity measure, from 87 consecutive women patients with RA attending a hospital clinic, and from 96 women community controls on a general practice list. A modified economic component of the Stanford Health Assessment Questionnaire was used to assess lost productivity. Results. Using a conservative model, the estimated total annual indirect costs (95% CI) were £7677 (£5560, £9794) for pSS, £10,444 (£8206, £12,681) for RA, and £892 (£307, £1478) for controls. Using a model that maximizes the estimates, the equivalent figures were £13,502 (£9542, £17,463), £17,070 (£13,112, £21,028), and £3382 (£2187, £4578), respectively. These were all significantly greater at p < 0.001 for patient groups than for the control group. Conclusion. pSS is associated with significantly increased indirect costs equivalent to 69%–83% of that for patients with RA. This needs to be taken into account when evaluating the overall economic consequences of pSS.